La medicina di precisione come opera d'arte collettiva.

Advancing our understanding of complex diseases necessitates an interdisciplinary dialogue beyond artificial intelligence (AI) in the field of medicine. Two decades after the completion of the Human Genome Project, genetic sequencing has facilitated targeted therapies for gene mutation-related ailments. However, this achievement has unveiled the immense gaps in our comprehension of life and disease mechanisms. Complex diseases, including cancer, diabetes, and autoimmune disorders, remain elusive due to their multifactorial nature. Consequently, a more holistic approach integrating AI with diverse scientific disciplines becomes imperative. This paper emphasizes the urgency of fostering collaboration among genetics, molecular biology, computational biology, and clinical research to unravel the intricate complexities underlying these diseases. By synergizing expertise and data from various domains, we can make significant strides towards unraveling the intricate web of complex diseases, leading to improved diagnosis, treatment, and ultimately, patient outcomes.

[Medical cannabis. Facilitate the proposal and sustainability for the training of healthcare personnel and the conduct of clinical trials in the cancer population.] / Cannabis terapeutica.

In light of the establishment of a permanent technical work table to address issues relating to cannabis for medical use, it is necessary to reflect free from ideological conditioning on the effectiveness and perception of the use of these "products" on the populations indicated in the regulatory note current. Taking a cue from two recently published works, which photograph a poor level of knowledge on medical cannabis by patients, caregivers, and healthcare professionals, we believe it is necessary to overcome ideological preconceptions by building educational programs and national guidelines that offer therapeutic opportunities based on solid scientific evidence.

Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition.

Cutaneous squamous cell carcinoma (cSCC) is the second most common type of non-melanoma skin cancer. Platinum-based regimens have been an integral part of palliative care for patients with locally advanced or metastatic disease. There is no evidence of efficacy for later lines of chemotherapy and no targeted therapy has been introduced as 'standard of care'. Here we report on the case of an elderly cSCC patient, resistant to conventional therapy, however successfully treated with anti-epidermal growth factor receptor (EGFR) agent (Cetuximab) in addition to a daily dose of Curcumin phospholipid. The patient responded to treatment and experienced no recurrence for 11 months with only minor skin-related toxicity. To our knowledge, this is the first report of clinical evidence that an anti EGFR targeted therapy with a daily oral dose of Curcumin phospholipid is well tolerated and results in a highly effective disease control in a heavily pretreated cSCC patient.